PARAGLIDEHF: Sacubitril/Valsartan versus valsartan on changes in NTproBNP, safety, and tolerability in patients with EF>40% stabilized after a WHF Event
Event:
Heart Failure 2023
Topic:
Pharmacotherapy
Session:
Late breaking clinical trials: medical therapy